Duration of increased bleeding tendency after cessation of aspirin therapy.
AuthorsCahill, Ronan A
McGreal, Gerard T
Crowe, Basil H
Ryan, Damien A
Manning, Brian J
Cahill, Mary R
Redmond, H Paul
AffiliationDepartment of Surgery, NUI (Cork), Cork University Hospital, Cork, Ireland.
Aspirin/*administration & dosage
Platelet Aggregation Inhibitors/*administration & dosage
Platelet Function Tests
MetadataShow full item record
CitationJ Am Coll Surg. 2005 Apr;200(4):564-73; quiz A59-61.
JournalJournal of the American College of Surgeons
AbstractBACKGROUND: Aspirin has a significant effect on hemostasis, so it is often recommended that patients taking aspirin discontinue treatment before elective surgery. While off aspirin, these patients may be at risk of thrombosis. The optimum period of time that aspirin should be withheld is controversial. The aim of this study was to establish the duration of the antihemostatic effect of prolonged aspirin therapy. STUDY DESIGN: In a prospective study, 51 healthy volunteers were randomly assigned into 3 groups, each receiving an identical tablet for 14 days. One group received a placebo tablet; individuals in the other two groups received either 75 mg or 300 mg of aspirin once a day. Template bleeding times and specific platelet function testing (using the PFA-100; Dade Behring) were carried out on subjects before therapy and again after its completion until they returned to baseline. RESULTS: Thirty-eight volunteers complied sufficiently with the protocol to provide useful results. All bleeding times normalized within 96 hours and all platelet function tests within 144 hours after stopping aspirin. There was no demonstrable hemostatic defect in any volunteer persisting by or beyond the sixth day after treatment cessation. There was no apparent difference in duration of effect between those taking either 75 mg or 300 mg of aspirin. CONCLUSIONS: This study uses sensitive measures of platelet function to demonstrate the duration of increased bleeding tendency after withdrawal of aspirin therapy. It supports discontinuation of aspirin therapy 5 days before elective surgery (with the operation being performed on the sixth day).
- Evaluation of the Clot Signature Analyzer as a hemostasis test in healthy volunteers exposed to low doses of aspirin.
- Authors: Igawa T, Kornhauser R, Cilla DD, King JO, Kambayashi J
- Issue date: 1999 Apr
- Duration of effects of aspirin on platelet function in healthy volunteers: an analysis using the PFA-100.
- Authors: Konrad CJ, Schuepfer GK, Gerber H, Rukwied R, Schmelz M, Schley M
- Issue date: 2006 Feb
- Perioperative monitoring of primary and secondary hemostasis in coronary artery bypass grafting.
- Authors: Hertfelder HJ, Bös M, Weber D, Winkler K, Hanfland P, Preusse CJ
- Issue date: 2005
- Aspirin non-responsiveness in Korean subjects on dual anti-platelet treatment determined by two different platelet function assays.
- Authors: Lee YW, Cho YH, Kim YH, Na JS, Shin HB, Ki CS, Choi TY, Lee YK
- Issue date: 2008 Spring
- Danqi Piantan Jiaonang does not modify hemostasis, hematology, and biochemistry in normal subjects and stroke patients.
- Authors: Gan R, Lambert C, Lianting J, Chan ES, Venketasubramanian N, Chen C, Chan BP, Samama MM, Bousser MG
- Issue date: 2008